Edwards Lifesciences Corporation $EW Shares Acquired by Sector Gamma AS

Sector Gamma AS grew its position in Edwards Lifesciences Corporation (NYSE:EW) by 32.1% during the fourth quarter, Holdings Channel reports. The firm owned 96,402 shares of the medical research company’s stock after acquiring an additional 23,422 shares during the period. Edwards Lifesciences makes up approximately 1.9% of Sector Gamma AS’s portfolio, making the stock its 20th largest position. Sector Gamma AS’s holdings in Edwards Lifesciences were worth $8,218,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of EW. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the third quarter valued at about $25,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter valued at about $28,000. Hilton Head Capital Partners LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter valued at about $28,000. Hantz Financial Services Inc. increased its holdings in shares of Edwards Lifesciences by 76.6% in the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 164 shares during the period. Finally, Dorato Capital Management acquired a new position in shares of Edwards Lifesciences in the fourth quarter valued at about $29,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Down 0.3%

Edwards Lifesciences stock opened at $85.75 on Friday. The firm has a market cap of $49.37 billion, a price-to-earnings ratio of 45.61, a price-to-earnings-growth ratio of 2.16 and a beta of 0.87. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $89.48. The business’s 50-day moving average price is $82.70 and its 200 day moving average price is $83.10. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. The firm had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.Edwards Lifesciences’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period last year, the company earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the sale, the chief financial officer directly owned 39,699 shares in the company, valued at approximately $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 81,038 shares of company stock valued at $6,683,255 in the last three months. 0.31% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on EW. Barclays reissued an “overweight” rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Mizuho set a $95.00 price objective on Edwards Lifesciences and gave the company an “outperform” rating in a report on Monday, April 13th. Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a research note on Wednesday, April 1st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Finally, TD Cowen reaffirmed a “buy” rating and set a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $95.96.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.